|
|
Pimecrolimus versus topical corticosteroids in dermatology.| Authors: | Chrysovalantis Korfitis, Stamatis Gregoriou, Efstathios Rallis, Dimitris Rigopoulos | | Language: | Eng. | | Date: | 30-07-2007 | | Journal: | Expert opinion on pharmacotherapy
(1744-7666)
| | Release: | Expert Opin Pharmacother. 2007 Jul;8(10):1565-73 | |
|
|
Abstract:
|
Pimecrolimus is an ascomycin macrolactam derivative with anti-inflammatory and immunomodulatory activity that belongs to the class of calcineurin inhibitors. It was developed after the attempt to discover alternatives to corticosteroids for the treatment of inflammatory skin diseases. Although pimecrolimus has been only approved for the treatment of atopic dermatitis, many clinical reports have proved its efficacy in a variety of skin conditions. However, corticosteroids remain the treatment of choice in inflammatory skin diseases. The possibility that pimecrolimus deserves a greater role in the long-term treatment of skin diseases is discussed herein by reviewing the published clinical studies that compare pimecrolimus and corticosteroids.
| | Copyright: | Expert opinion on pharmacotherapy
University of Athens, Department of Dermatology, A. Sygros' Hospital, Athens, Greece. | | Full text: |  EBSCO - HTML (needs subscription) | | Terms: | Administration, Cutaneous, Adrenal Cortex Hormones, Anti-Inflammatory Agents, Dermatitis, Dermatologic Agents, Dermatology, Drug Administration Schedule, Drug Labeling, Humans, Practice Guidelines as Topic, Tacrolimus, Treatment Outcome | | |
|
|
|
|  Add to my archive |
Articles from other specialties: Nursing, Plastic Surgery, Thoracic Surgery, Sports Medicine, Haematology, Oncology, Nuclear Medicine, Neurosurgery, Preventive Medicine, Ophtalmology, Psychiatry, Gastrointestinal Surgery |
